AR108671A1 - Análogos de diamida imidodicarbonimidica - Google Patents

Análogos de diamida imidodicarbonimidica

Info

Publication number
AR108671A1
AR108671A1 ARP170101515A ARP170101515A AR108671A1 AR 108671 A1 AR108671 A1 AR 108671A1 AR P170101515 A ARP170101515 A AR P170101515A AR P170101515 A ARP170101515 A AR P170101515A AR 108671 A1 AR108671 A1 AR 108671A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
independently
alkyl
heterocycloalkyl
nr5r6
Prior art date
Application number
ARP170101515A
Other languages
English (en)
Original Assignee
Enlibrium Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enlibrium Inc filed Critical Enlibrium Inc
Publication of AR108671A1 publication Critical patent/AR108671A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud está dirigida a compuestos de diamida imidodicarbonimidica, y sus sales, solvatos o estereoisómeros farmacéuticamente aceptables. También proporciona composiciones y el uso de tales composiciones en métodos para tratar el cáncer, la diabetes o el síndrome de ovario poliquístico. Reivindicación 1: Un compuesto que tiene la estructura de fórmula (1) donde: cada R¹ es independientemente halógeno, -CN, -NO₂, -OR⁴, -NR⁴R⁴, alquilo C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -C(O)R³, -OC(O)R³, -CO₂R⁴, -N(R⁴)C(O)R³, -C(O)NR⁵R⁶, -N(R⁴)C(O)NR⁵R⁶, -S(O)₂R³, -N(R⁴)S(O)₂R³, o -S(O)₂NR⁵R⁶; cada R² es independientemente alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; cada R³ es independientemente alquilo C₁₋₆; cada R⁴ es independientemente H o alquilo C₁₋₆; cada R⁵ y cada R⁶ son independientemente H o alquilo C₁₋₆; o R⁵ y R⁶ junto con el átomo de nitrógeno al cual están unidos forman un heterocicloalquilo C₁₋₆ opcionalmente sustituido; p es 0, 1, 2, 3, 4 ó 5; y q es 0, 1, 2, 3 ó 4; o una sal, un solvato o un estereoisómero farmacéuticamente aceptable de este. Reivindicación 18: Un compuesto de fórmula (2) donde: cada R¹ es independientemente halógeno, -CN, -NO₂, -OR⁴, -NR⁴R⁴, alquilo C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -C(O)R³, -OC(O)R³, -CO₂R⁴, -N(R⁴)C(O)R³, -C(O)NR⁵R⁶, -N(R⁴)C(O)NR⁵R⁶, -S(O)₂R³, -N(R⁴)S(O)₂R³, o -S(O)₂NR⁵R⁶; cada R² es independientemente alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; cada R³ es independientemente alquilo C₁₋₆; cada R⁴ es independientemente H o alquilo C₁₋₆; cada R⁵ y cada R⁶ son independientemente H o alquilo C₁₋₆; o R⁵ y R⁶ junto con el átomo de nitrógeno al cual están unidos forman un heterocicloalquilo C₁₋₆ opcionalmente sustituido; p es 1, 2, 3, 4 ó 5; y q es 0, 1, 2, 3 ó 4; o una sal, un solvato o un estereoisómero farmacéuticamente aceptable de este. Reivindicación 34: Un compuesto de fórmula (3) donde: cada R¹ es independientemente halógeno, -CN, -NO₂, -NR⁴R⁴, alquilo C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -C(O)R³, -OC(O)R³, -CO₂R⁴, -N(R⁴)C(O)R³, -C(O)NR⁵R⁶, -N(R⁴)C(O)NR⁵R⁶, -S(O)₂R³, -N(R⁴)S(O)₂R³, o -S(O)₂NR⁵R⁶; cada R² es independientemente alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; cada R³ es independientemente alquilo C₁₋₆; cada R⁴ es independientemente H o alquilo C₁₋₆; cada R⁵ y cada R⁶ son independientemente H o alquilo C₁₋₆; o R⁵ y R⁶ junto con el átomo de nitrógeno al cual están unidos forman un heterocicloalquilo C₁₋₆ opcionalmente sustituido; n es 0 ó 1; p es 1, 2, 3 ó 4; y q es 0, 1, 2, 3 ó 4; o una sal, un solvato o un estereoisómero farmacéuticamente aceptable de este. Reivindicación 51: Un compuesto de fórmula (4) donde: cada R¹ es independientemente -CN, -NR⁴R⁴, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, -C(O)R³, -OC(O)R³, -CO₂R⁴, -N(R⁴)C(O)R³, -C(O)NR⁵R⁶, -N(R⁴)C(O)NR⁵R⁶, -S(O)₂R³, -N(R⁴)S(O)₂R³, o -S(O)₂NR⁵R⁶; cada R² es independientemente alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, heterocicloalquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; cada R³ es independientemente alquilo C₁₋₆; cada R⁴ es independientemente H o alquilo C₁₋₆; cada R⁵ y cada R⁶ son independientemente H o alquilo C₁₋₆; o R⁵ y R⁶ junto con el átomo de nitrógeno al cual están unidos forman un heterocicloalquilo C₁₋₆ opcionalmente sustituido; p es 1, 2, 3, 4 ó 5; y q es 0, 1, 2, 3 ó 4; o una sal, un solvato o un estereoisómero farmacéuticamente aceptable de este.
ARP170101515A 2016-06-03 2017-06-02 Análogos de diamida imidodicarbonimidica AR108671A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662345708P 2016-06-03 2016-06-03

Publications (1)

Publication Number Publication Date
AR108671A1 true AR108671A1 (es) 2018-09-12

Family

ID=60479127

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101515A AR108671A1 (es) 2016-06-03 2017-06-02 Análogos de diamida imidodicarbonimidica

Country Status (2)

Country Link
AR (1) AR108671A1 (es)
WO (1) WO2017210580A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2023209611A1 (en) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254593A (en) * 1984-03-19 1993-10-19 The Rockefeller University Compositions containing biguanides and derivatives thereof as inhibitors of nonenzymatic cross-linking
WO2000062626A1 (en) * 1999-04-15 2000-10-26 Fox Chase Cancer Center Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
US7256218B2 (en) * 2002-11-22 2007-08-14 Jacobus Pharmaceutical Company, Inc. Biguanide and dihydrotriazine derivatives
CN101652131A (zh) * 2007-01-29 2010-02-17 韩兀制药株式会社 N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
US9480663B2 (en) * 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
WO2013022280A2 (en) * 2011-08-08 2013-02-14 Hanall Biopharma Co., Ltd. N1-cyclic amine-n2-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
WO2017210580A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
AR095339A1 (es) Compuestos moduladores alostericos de la hemoglobina
AR094537A1 (es) COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
AR103833A1 (es) Compuestos bicíclicos de sulfonamida cetona
AR099955A1 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
AR094452A1 (es) COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR090868A1 (es) Composiciones plaguicidas y procesos relacionados con ellas
AR103252A1 (es) Compuestos de quinazolina
AR093403A1 (es) COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094702A1 (es) Compuestos de azabencimidazol
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR108010A1 (es) Derivados de indolina y su uso como inhibidores de ews-fli1
AR102222A1 (es) Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos
AR097795A1 (es) Derivados de n-arilmetilo sulfonamida como moduladores negativos de nr2a
AR112900A1 (es) Compuesto derivado de pirazol y uso de este
AR108671A1 (es) Análogos de diamida imidodicarbonimidica
AR109712A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR097794A1 (es) Moduladores octahidro-ciclopenta[c]pirrol negativos de nr2b

Legal Events

Date Code Title Description
FB Suspension of granting procedure